Our findings do not suggest high utilization of neoadjuvant chemotherapy is associated with a trade-off between perioperative and long-term outcomes,” the researchers wrote.

In analysis of 5268 women from the first childbirth, the proportion of treated women began to decline 18 months before childbirth.

The UP-AA clinical program includes 2 studies assessing the safety and efficacy of upadacitinib in adults and adolescent patients with severe alopecia areata.

SURPASS-CVOT evaluated the efficacy and safety of tirzepatide compared with dulaglutide in adults with T2D and a confirmed ASCVD.